ABIONYX Pharma SA (EPA:ABNX)

Market Cap	44.32M
Revenue (ttm)	4.60M
Net Income (ttm)	-4.40M
Shares Out	34.68M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,443
Average Volume	39,596
Open	1.280
Previous Close	1.280
Day's Range	1.272 - 1.280
52-Week Range	0.981 - 1.500
Beta	0.48
RSI	52.23
Earnings Date	Mar 6, 2025

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteine...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 61
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABNX

Financial Performance

In 2024, ABIONYX Pharma's revenue was 4.60 million, a decrease of -0.86% compared to the previous year's 4.64 million. Losses were -4.40 million, 25.1% more than in 2023.